Boehringer Ingelheim has entered into a multi-year strategic partnership with TARGET PharmaSolutions, a real-world clinical data company, for an observational study TARGET-NASH.
This study is evaluating patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) and has enrolled 2,423 patients at 55 sites, with the expectation to enroll as many as 15,000 patients over the coming years.
The TARGET model organizes a community of stakeholders, including pharmaceutical manufacturers, key opinion leaders, regulatory agencies, investigators, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes.
Meg Powell, chief executive officer of TARGET PharmaSolutions, said, "We are very excited to have Boehringer Ingelheim join TARGET-NASH as an industry partner. We have exceeded our enrollment targets to date, and we are providing valuable real-world data and insight on NASH patients that will have a significant impact on the scientific understanding of the natural history and treatment modalities for NASH. This data, combined with the TARGET-NASH biorepository and patient reported outcomes, will enable our collaborators to continue to increase their understanding of this growing disease."
Breaking News
Boehringer, TARGET Pharma in Strategic NASH Pact
Observational study to incorporate TARGET model of community of stakeholders
10.19.17
Related Breaking News
-
Breaking News | Clinical Trials | Trials & Filings
SGS to Initiate Malaria Challenge Trial in Belgium
Trial to test the efficacy of MMV’s experimental compound in killing malaria parasites in the liver before they can develop and reach the bloodstream02.12.19
-
Breaking News | Clinical Trials | Industry News | Information Technology
Boehringer, IBM Explore Blockchain Technology in Clinical Trials
Aims to improve the quality of clinical trial processes and record keeping02.12.19
-
Breaking News | Industry News | Information Technology | Inspections | QA/QC | Regulatory Affairs | Validation
Top Global Pharma Company to Implement ValGenesis' VLMS
Paperless validation system aims to harmonize and standardize the validation process across all its global sites02.12.19
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
NeoTX, MedImmune Announce Clinical Collaboration
To support Phase 1b/2 studies investigating ANYARA in combination with AstraZeneca's IMFINZI02.11.19
-
Breaking News | Industry News | Information Technology
-
Breaking News | Industry News | Information Technology
ICON Launches Drug Safety Reporting Solution
Developed on platform deploying rule-based automation for timely delivery of drug safety information02.05.19
-
Breaking News | Clinical Trials | CRO News | Drug Development
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
Neurotrope & NCI Enter Development Agreement
To develop a Phase I clinical trial testing the safety and toxicity of Bryostatin-1 in children and young adults with CD22 + leukemia and B-cell lymphoma02.04.19
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
Fortress' Caelum Enters Partnership with Alexion
To advance the development of CAEL-101 for light chain (AL) amyloidosis01.31.19
-
Breaking News | Clinical Trials | Drug Development | Trials & Filings
Roche Discontinues Phase III Crenezumab Studies in Early AD
Interim analysis indicates crenezumab was unlikely to meet the primary endpoint01.30.19
-
Breaking News | Clinical Trials | Industry News | QA/QC
WCG, Prudentia Enter Pharmacovigilance Alliance
Aims to deliver a comprehensive solution aimed at enhancing the quality, safety and regulatory compliance of adverse event monitoring in drug development01.29.19
-
Bio News | Breaking News | Clinical Trials | Collaborations & Alliances | Drug Development | Industry News
Servier, Allogene Expand Clinical CAR T Tie-up
Announces FDA clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T therapy01.28.19
-
Breaking News | Clinical Trials | Collaborations & Alliances | Drug Development
Evotec Earns Second Genome Milestone
Initiates Phase II study of SGM-1019, a first-in-class oral therapeutic for the treatment of nonalcoholic steatohepatitis01.24.19
-
Breaking News | Industry News | Information Technology
ChargePoint Expands Smart Monitoring Technology into North America
Achieves HazLoc certification for its VERIFI system01.24.19
-
Analytical Services | Bio News | Industry News | Information Technology | R&D
Quanticate Launches QVigilance
For the support of small and mid-size companies transitioning from clinical trials to post-marketing and establishing compliant PV systems01.16.19
